journal
MENU ▼
Read by QxMD icon Read
search

Journal of Viral Hepatitis

journal
https://www.readbyqxmd.com/read/29316078/occult-hbv-infection-in-hiv-infected-adults-and-evaluation-of-pooled-nat-for-hbv
#1
T R Dinesha, J Boobalan, S Sivamalar, D Subashini, Sunil S Solomon, K G Murugavel, P Balakrishnan, Davey M Smith, S Saravanan
The study aimed to determine the prevalence of occult Hepatitis B virus (HBV) infection among HIV infected persons, and to evaluate the use of a pooling strategy to detect occult HBV infection in the setting of HIV infection. Five hundred and two HIV positive individuals were tested for HBV, occult HBV, and Hepatitis C and D with serologic and nucleic acid testing (NAT). We also evaluated a pooled NAT strategy for screening occult HBV infection among the HIV-positive individuals. The prevalence of HBV infection among HIV positive individuals was 32 (6...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29316069/entecavir-and-tenofovir-reduce-hepatitis-b-virus-related-hepatocellular-carcinoma-recurrence-more-effectively-than-other-antivirals
#2
Hyeki Cho, Hongkeun Ahn, Dong Hyeon Lee, Jeong-Hoon Lee, Yong Jin Jung, Young Chang, Joon Yeul Nam, Young Youn Cho, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Jeong Min Lee, Yoon Jun Kim, Jung-Hwan Yoon
Nucleos(t)ide analogues (NAs) have been shown to decrease the risk of hepatocellular carcinoma (HCC) recurrence. This study evaluated whether high-potency NAs (entecavir and tenofovir disoproxil fumarate [TDF]) reduce the risk of tumor recurrence more potently than low-potency NAs after curative treatment of hepatitis B virus (HBV)-related HCC. This study included 607 consecutive HBV-related HCC patients treated with surgical resection or radiofrequency ablation. The patients were categorized into three groups according to antiviral treatment: group A (no antiviral; n=261), group B (low-potency NA; n=90), and group C (high-potency NA; n=256)...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29316067/deep-sequencing-shows-low-level-oncogenic-hepatitis-b-virus-variants-persisting-post-liver-transplant-despite-potent-anti-hbv-prophylaxis
#3
Keith Ck Lau, Carla Osiowy, Elizabeth Giles, Beth Lusina, Guido van Marle, Kelly W Burak, Carla S Coffin
Recent studies suggest that withdrawal of hepatitis B immune globulin (HBIG) and nucleos(t)ide analogues (NA) prophylaxis may be considered in HBV surface antigen (HBsAg) negative liver transplant (LT) recipients with a low risk of disease recurrence. However, the frequency of occult HBV infection (OBI) and HBV variants after LT in the current era of potent NA therapy is unknown. 12 LT recipients on prophylaxis were tested in matched plasma and peripheral blood mononuclear cells (PBMC) for HBV quasispecies by in-house nested PCR and next generation sequencing of amplicons...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29316039/treatment-of-hcv-infection-in-poland-at-the-beginning-of-the-interferon-free-era-the-epiter-2-study
#4
Robert Flisiak, Dorota Zarębska-Michaluk, Ewa Janczewska, Agnieszka Staniaszek, Andrzej Gietka, Włodzimierz Mazur, Magdalena Tudrujek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Dorota Dybowska, Waldemar Halota, Beata Lorenc, Marek Sitko, Aleksander Garlicki, Hanna Berak, Andrzej Horban, Iwona Orłowska, Krzysztof Simon, Łukasz Socha, Marta Wawrzynowicz-Syczewska, Jerzy Jaroszewicz, Zbigniew Deroń, Agnieszka Czauż-Andrzejuk, Jolanta Citko, Rafał Krygier, Anna Piekarska, Łukasz Laurans, Witold Dobracki, Jolanta Białkowska, Olga Tronina, Małgorzata Pawłowska
The aim of the EpiTer-2 study was to analyze patient characteristics and their medication for HCV infection in Poland at the beginning of the interferon-free era. Analysis of data of HCV infected patients treated during the initial period of availability of interferon-free regimens in Poland, who started therapy after 1 July 2015 and had available an efficacy evaluation report before 30 June 2017 was undertaken. A total of 2879 patients with chronic hepatitis C were entered, including 46% with liver cirrhosis...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29316037/development-of-a-recombinant-murine-tumor-model-using-hepatoma-cells-expressing-hepatitis-c-virus-hcv-non-structural-antigens
#5
K Young, K Haq, S MacLean, R Dudani, S M Elahi, R Gilbert, R Weeratna, L Krishnan
Hepatitis C virus (HCV) chronically infects 2-3% of the world's population, causing liver disease and cancer with prolonged infection. The narrow host range of the virus, being restricted largely to human hepatocytes, has made the development of a relevant infection and reliable model to evaluate the efficacy of vaccines a challenge. We have developed a novel approach to accomplish this by generating a murine hepatoma cell line stably expressing non-structural HCV antigens which can be used in vitro or in vivo to test HCV vaccine efficacies...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29316030/understanding-and-addressing-hepatitis-c-reinfection-in-the-oral-direct-acting-antiviral-era
#6
Oluwaseun Falade-Nwulia, Mark S Sulkowski, Alana Merkow, Carl Latkin, Shruti H Mehta
The availability of effective, simple, well tolerated oral direct acting antiviral (DAA) hepatitis C regimens have raised optimism for HCV elimination at the population level. HCV reinfection in key populations such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM) however threatens the achievement of this goal both from a patient, provider and population perspective. The goal of this review is to synthesize our current understanding of estimated rates and factors associated with HCV reinfection...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29316001/directly-observed-therapy-of-chronic-hepatitis-c-with-ledipasvir-sofosbuvir-in-people-who-inject-drugs-at-risk-for-non-adherence-to-direct-acting-antivirals
#7
Angelika Schütz, Stephan Moser, Cornelia Schwanke, Raphael Schubert, Julian Luhn, Enisa Gutic, Tobias Lang, Michael Schleicher, Hans Haltmayer, Michael Gschwantler
An important subgroup of people who inject drugs (PWID) receiving opioid agonist therapy (OAT), cannot be treated in the setting of a hepatology center and would not regularly ingest their medication when handed to them for self-administration. Our hypothesis was that chronic hepatitis C in these patients could be ideally managed if modern, interferon-free regimens were administered together with OAT under direct observation of a physician or nurse at a low-threshold facility. In this open-label, non-interventional, proof-of-concept study (ClinicalTrials...
January 5, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29274197/increased-recurrence-rates-of-hepatocellular-carcinoma-after-daa-therapy-in-a-hepatitis-c-infected-egyptian-cohort-a-comparative-analysis
#8
Mohamed El Kassas, Anna L Funk, Mohamed Salaheldin, Yusuke Shimakawa, Mohammed Eltabbakh, Kévin Jean, Adel El Tahan, Ahmad T Sweedy, Shimaa Afify, Naglaa Fa Youssef, Gamal Esmat, Arnaud Fontanet
In Egypt, hepatocellular carcinoma (HCC) is the most common form of cancer and direct acting antivirals (DAA) are administered on a large scale to patients with chronic HCV infection to reduce the risk. In this unique setting, we aimed to determine the association of DAA exposure with early phase HCC recurrence in patients with a history of HCV-related liver cancer. This was a prospective cohort study of an HCV infected population from one Egyptian specialized HCC management center starting from the time of successful HCC intervention...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29274193/efficacy-and-safety-of-6-or-8-weeks-of-simeprevir-daclatasvir-sofosbuvir-for-hcv-genotype-1-infection
#9
M S Sulkowski, J J Feld, E Lawitz, F Felizarta, A M Corregidor, O Khalid, R Ghalib, W B Smith, V Van Eygen, D Luo, L Vijgen, M Gamil, T N Kakuda, S Ouwerkerk-Mahadevan, P Van Remoortere, M Beumont
The phase 2, open-label ACCORDION (ClinicalTrials. gov: NCT02349048) study investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week regimen of simeprevir, daclatasvir and sofosbuvir in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype (GT) 1 infection and either early-stage fibrosis or compensated cirrhosis. Patients were assigned to treatment groups according to their fibrosis stage. Early-stage fibrosis: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once daily for 6 weeks; compensated cirrhosis: same regimen for 8 weeks...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29274192/uptake-of-direct-acting-antiviral-treatment-for-chronic-hepatitis-c-in-australia
#10
Behzad Hajarizadeh, Jason Grebely, Gail V Matthews, Marianne Martinello, Gregory J Dore
A Government-funded interferon-free direct acting antiviral (DAA) treatment program for chronic hepatitis C virus (HCV) infection has been available in Australia since March 2016. This study assessed the levels and patterns of DAA treatment uptake during March-December 2016 in Australia, and described the key features in development of the program. All prescriptions in Australia are submitted to the Pharmaceutical Benefits Scheme by dispensing pharmacies. Data on dispensed DAA prescriptions for a longitudinal cohort of individuals, representing a 10% random sample of the Pharmaceutical Benefits Scheme database, were used for estimating DAA treatment uptake and sub-group analyses...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29274189/the-incidence-and-predictors-of-hbv-relapse-after-cessation-of-tenofovir-therapy-in-chronic-hepatitis-b-patients
#11
Chien-Hung Chen, Yao-Chun Hsu, Sheng-Nan Lu, Chao-Hung Hung, Jing-Houng Wang, Chuan-Mo Lee, Tsung-Hui Hu
This study investigates the incidences and predictors of hepatitis B virus (HBV) relapse after tenofovir disoproxil fumarate (TDF) therapy in hepatitis B e antigen (HBeAg)-positive and -negative patients. We retrospectively recruited 143 chronic hepatitis B (CHB) patients without cirrhosis (39 HBeAg-positive and 104 HBeAg-negative patients) who were previously treated with TDF and had post-treatment follow-up for at least 6 months (median: 55, IQR 36-85 weeks). All the patients fulfilled the stopping criteria of APASL 2012...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29274188/the-presence-of-multiple-ns5a-rass-is-associated-with-the-outcome-of-sofosbuvir-and-ledipasvir-therapy-in-ns5a-inhibitor-na%C3%A3-ve-patients-with-chronic-hcv-genotype-1b-infection-in-a-real-world-cohort
#12
Ritsuzo Kozuka, Hoang Hai, Hiroyuki Motoyama, Atsushi Hagihara, Hideki Fujii, Sawako Uchida-Kobayashi, Hiroyasu Morikawa, Masaru Enomoto, Yoshiki Murakami, Norifumi Kawada, Akihiro Tamori
It is unclear whether multiple non-structural (NS) 5A resistance-associated substitutions (RASs) correlate with the outcome of sofosbuvir (SOF) and ledipasvir (LDV) therapy. We investigated the effects of multiple NS5A RASs in NS5A inhibitor-naïve patients with chronic hepatitis C virus genotype 1b infection treated with SOF/LDV. In 313 patients treated with SOF/LDV, we assessed the effects of multiple NS5A RASs on the sustained virological response (SVR). RASs at L28, R30, L31, Q54, P58, Q62, A92, and Y93 in the NS5A region were examined by direct sequencing...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29274184/prevalence-of-mixed-genotype-hepatitis-c-virus-infections-in-the-uk-as-determined-by-genotype-specific-pcr-and-deep-sequencing
#13
A L McNaughton, V B Sreenu, G Wilkie, R Gunson, K Templeton, E C McWilliam Leitch
The incidence of mixed genotype hepatitis C virus infections in the UK is largely unknown. As the efficacy of direct acting antivirals is variable across different genotypes, treatment regimens are tailored to the infecting genotype, which may pose issues for the treatment of underlying genotypes within undiagnosed mixed genotype HCV infections. There is therefore a need to accurately diagnose mixed genotype infections prior to treatment. PCR-based diagnostic tools were developed to screen for the occurrence of mixed genotype infections caused by the most common UK genotypes, 1a and 3, in a cohort of 506 individuals diagnosed with either of these genotypes...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29274178/assessing-uncertainty-in-the-burden-of-hepatitis-c-virus-comparison-of-estimated-disease-burden-and-treatment-costs-in-the-uk
#14
Finn Gubay, Roisin Staunton, Cornelia Metzig, Ibrahim Abubakar, Peter J White
Hepatitis C virus (HCV) is a major and growing public health concern. We need to know the expected health burden and treatment cost, and understand uncertainty in those estimates, to inform policy-making and future research. Two models that have been important in informing treatment guidelines and assessments of HCV burden were compared by simulating cohorts of individuals with chronic HCV infection initially aged 20, 35, and 50 years. One model predicts that health losses (measured in Quality-Adjusted Life-Years (QALYs)) and treatment costs decrease with increasing initial age of the patients, whilst the other model predicts that below 40 years, costs increase and QALY losses change little with age, and above 40 years they decline with increasing age...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29274174/prophylactic-antiviral-therapy-for-the-prevention-of-mother-to-child-transmission-of-hepatitis-b-virus-can-be-stopped-at-delivery
#15
Qing-Lei Zeng, Guang-Hua Xu, Ben Wang, Zhi-Qin Li, Zu-Jiang Yu
Many studies have demonstrated that antiviral therapy has an important role in the prevention of mother-to-child transmission of hepatitis B virus (HBV)1-3 , including a recent article by Han et al. who reported that the majority of mothers stopped prophylactic telbivudine at 1 month postpartum.4 However, the HBV Guidelines of the AASLD (at delivery to 3 months postpartum),1 EASL (within and at 12 weeks postpartum in 2012 and 2017, respectively),2 and APASL (at delivery)3 had different recommendations regarding stopping time of antivirals given as prophylaxis, which result in differing durations worldwide...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29239130/establishing-the-cascade-of-care-for-hepatitis-c-in-england-benchmarking-to-monitor-impact-of-direct-acting-antivirals
#16
Ruth Simmons, Georgina Ireland, Will Irving, Matthew Hickman, Caroline Sabin, Samreen Ijaz, Mary Ramsay, Sam Lattimore, Sema Mandal
Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case-finding, referral, treatment uptake and retention in care. Using data from the Sentinel Surveillance of Blood Borne Virus testing (SSBBV) between 2005-2014 we investigate the continuum of care of those tested for HCV in England. Persons ≥1 years old, with an anti-HCV test and subsequent RNA tests between 2005-2014 reported to SSBBV were collated...
December 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29239080/hcv-positive-lymphoma-after-sustained-virological-response-with-direct-acting-antiviral-agents-the-game-is-not-over-after-hcv-eradication
#17
E Rodríguez de Santiago, K Velázquez Kennedy, M García González, F Gea Rodríguez, L Téllez Villajos, E Tavío Hernández, A Albillos Martínez
We read with interest the study published by Schiavinato A. et al. entitled: " Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents"[1]. There is extensive data supporting the association between hepatitis C virus (HCV) and B-cell non-Hodgkin lymphoma (B-cell NHL), especially with marginal zone and diffuse large B-cell NHL subtypes. Antiviral treatment with Interferon-based regimens has been shown to improve prognosis and can be curative in some cases of indolent lymphoma...
December 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29239069/the-antiviral-role-of-zinc-and-metallothioneins-in-hepatitis-c-infection
#18
Scott A Read, Grant Parnell, David Booth, Mark W Douglas, Jacob George, Golo Ahlenstiel
Metallothioneins (MTs) are small, cysteine rich proteins characterized by a high affinity for monovalent and divalent cations, such as copper and zinc. Of the four known metallothionein isoforms, only members of the metallothionein 1 and 2 subfamilies are widely expressed, acting as metal chaperones whose primary role is to mediate intracellular zinc homeostasis. Metallothioneins are potently induced by heavy metals and other sources of oxidative stress where they facilitate metal binding and detoxification as well as free radical scavenging...
December 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29239068/estimating-chronic-hepatitis-c-prognosis-using-transient-elastography-based-liver-stiffness-a-systematic-review-and-meta-analysis
#19
Aysegul Erman, Abhinay Sathya, Austin Nam, Joanna M Bielecki, Jordan J Feld, Hla-Hla Thein, William W L Wong, Paul Grootendorst, Murray D Krahn
Chronic hepatitis C (CHC) is a leading cause of hepatic fibrosis and cirrhosis. The level of fibrosis is traditionally established by histology and prognosis is estimated using fibrosis progression rates (FPRs; annual probability of progressing across histological stages). However, newer non-invasive alternatives are quickly replacing biopsy. One alternative, transient elastography (TE), quantifies fibrosis by measuring liver stiffness (LSM). Given these developments, the purpose of this study was (1) to estimate prognosis in treatment-naïve CHC patients using TE-based liver stiffness progression rates (LSPR) as an alternative to FPRs and (2) to compare consistency between LSPRs and FPRs...
December 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29230907/comparative-evaluation-of-gpr-versus-apri-and-fib-4-in-predicting-different-levels-of-liver-fibrosis-of-chronic-hepatitis-b
#20
D-P Liu, W Lu, Z-Q Zhang, Y-B Wang, R-R Ding, X-L Zhou, D Huang, X-F Li
It is of great significance to develop and evaluate noninvasive indexes predicting the level of liver fibrosis. The aim of this study was to comparatively evaluate gamma-glutamyl transpeptidase-to-platelet ratio (GPR) versus aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on 4 factors (FIB-4) in predicting different levels of liver fibrosis of chronic hepatitis B (CHB) within the framework of HBeAg-positive and HBeAg-negative patients. A total of 1157 HBeAg-positive and 859 HBeAg-negative CHB patients were enrolled, among whom the pathological stage ≥S2, ≥S3, ≥S4 were defined as significant fibrosis, extensive fibrosis and cirrhosis, respectively...
December 12, 2017: Journal of Viral Hepatitis
journal
journal
32017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"